Although systemic sclerosis (SSc) is a multisystem disease, signs and symptoms of neurological involvement are unusual, and in contrast to the situation in other connective tissue disorders, vasculitis is thought to be rare. We report a 51 year old man with diffuse SSc who developed vasculitis affecting peripheral nerve and muscle, and subsequently generalised seizures.
He first became unwell in 1985, aged 45 years, when he developed fibrosing alveolitis. Subsequently he developed arthralgias, Raynaud's phenomenon, vasculitic lesions of his finger-tips and mild proximal muscle weakness with elevated creatine phosphokinase (CPK). In 1987 sclerodactyly and skin tethering of the anterior abdominal wall were noted, and skin biopsy of both involved and clinically uninvolved skin showed features of SSc with intimal thickening, oedema and a mild inflammatory cell infiltrate. As well as diffuse skin thickening he went on to develop oesophageal dysmotility, heart block requiring a permanent cardiac pacemaker (but no Letters to the editor generally observed in our patients with SSc'0 but were not, however, present in the high titres characteristically associated with the vasculopathy of the antiphospholipid syndrome. In our laboratory such patients would typically have IgG levels in excess of 50 units/ml.
In conclusion, vasculitis was an important factor in the pathogenesis of our patient's disease, and the possibility of vasculitis should be considered in patients with SSc, especially in those with atypical clinical features. Necropsy findings suggested that treatment with steroids and immunosuppressants did suppress this vasculitis but was unable to prevent the progressive deterioration in the patient's overall condition. Behqet's disease was diagnosed. Therapy with various doses of colchicine, cyclophosphamide, prednisolone, and cyclosporine was ineffective.
Starting in April 1991, FK506 (6 mg/day) was added to the prednisolone regime (5 mg/day), which he had been receiving continuously since 1982. In October 1991, he began to experience general fatigue, headache, and high fever. Dizziness and arthralgia began on 3 December and nausea on 20 December. He vomited three days later and was admitted to our hospital the next day. An increase in the number of cells, protein concentration, and Q albumin in CSF, and an area of high signal intensity on the T2-weighted images in the pons and right cerebral peduncle on MRI were revealed at the time of admission. But weekly or biweekly examination of CSF and MRI repeated after admission showed gradual improvement after the discontinuation of FK506 (24 December) without any additional treatment. These improvements paralleled improvements in symptoms.
The second case (a 45 year old woman) was diagnosed in 1989 with Behcet's disease by recurrent oral ulceration, genital ulcers, and refractory uveitis. FK506 (4 mg/day) was added to colchicine on 26 September in 1991. On 15 February the following year, she began to experience headaches, nausea, vomiting, and faintness. Amnesia and stupor began on 19 February and she was admitted to our hospital three days later. At the time of admission, there were abnormal findings from the CSF ( 
